TICKERNERD
Menu
EMBCEMBCHealthcare · Medical Instruments & Supplies

EMBC Stock Forecast: Embecta Corp. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$5.23
−4.39% on the day

The 4 Wall Street analysts covering Embecta Corp. hold a median 12-month price target of $4 — -23.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 21 Aug 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$296.3M
Ticker Nerd rank
84 / 100
Median analyst target
$4.00
Analysts covering
4
Total return, dividends reinvested
1W
+2.5%
1M
+55.2%
YTD
−55.2%
1Y
−60.6%
From 52W high
−64.8%
From 52W low
+80.8%
$3
$15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EMBC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Embecta Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Aug 2026
84 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
100
Issuance
91
Quality
88
Volatility
71
Revisions
69
Accruals
62
Size
62
Growth
31
Momentum
10

Value (100): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (10): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EMBC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EMBC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2$4$6$8$10$12$14$16Oct 25Jan 26Apr 26Jul 26EMBCHigh $5.00Median $4.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
0 Buy3 Hold1 Sell
Low $3.00Median $4.00High $5.00

The green dot is the last close — the median target sits −23.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 May 2026B of A SecuritiesMaintainsUnderperform$11 → $3.00
6 May 2026BTIGDowngradeNeutral—
6 May 2026MizuhoMaintainsNeutral—
13 Apr 2026MizuhoMaintainsNeutral—
6 Feb 2026BTIGReiteratesBuy—
5 Sept 2025BTIGReiteratesBuy—
16 July 2025MizuhoMaintainsNeutral—
23 May 2025MizuhoMaintainsNeutral—
10 Apr 2025MizuhoInitiatesNeutral—
27 Nov 2024BTIGUpgradeBuy—
15 July 2024Morgan StanleyMaintainsUnderweight—
10 May 2024Morgan StanleyMaintainsUnderweight—
22 Nov 2023Morgan StanleyMaintainsUnderweight—
18 Oct 2023Morgan StanleyMaintainsUnderweight—
24 Aug 2023Morgan StanleyMaintainsUnderweight—
18 July 2023Morgan StanleyMaintainsUnderweight—
15 May 2023Morgan StanleyMaintainsUnderweight—
6 Jan 2023Morgan StanleyDowngradeUnderweight—
21 Dec 2022Morgan StanleyMaintainsEqual-Weight—
11 Oct 2022Morgan StanleyMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EMBC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

EMBC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+16.9%
Analysts raising
3
Analysts cutting
0
Fundamentals

Embecta Corp. (EMBC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.6×

Cheaper than 68% of US stocks

Price / sales
0.3×

Cheaper than 90% of US stocks

Price / book
−0.5×

Cheaper than 94% of US stocks

EV / EBITDA
5.7×

Cheaper than 52% of US stocks

Growth & margins
Revenue growth (YoY)
−8.1%

Higher than 17% of US stocks

Earnings growth (YoY)
−53.6%

Higher than 9% of US stocks

Gross margin
56.4%

Higher than 69% of US stocks

Operating margin
23.7%

Higher than 83% of US stocks

Net margin
8.6%

Higher than 67% of US stocks

Returns & dividend
Return on equity
−14.6%

Higher than 33% of US stocks

Return on assets
12.2%

Higher than 95% of US stocks

Dividend yield
0.8%

Higher than 16% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

EMBC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
EMBCEmbecta Corp.$296.3M
84
SMTISanara MedTech, Inc.$306.7M
91
OSUROraSure Technologies, Inc.$268.2M
88
UTMDUtah Medical Products, Inc.$227.8M
78
PDEXPro-Dex, Inc.$209.7M
86
ANGOAngioDynamics, Inc.$648.9M
90
KRMDKORU Medical Systems, Inc.$147.4M
96

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Embecta Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EMBC news & analysis

EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

Newsfile Corp · 18 Aug 2026negative

Bernstein Liebhard LLP announced it is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. (NASDAQ: EMBC). The law firm aims to determine whether the company's leadership fulfilled its obligations to shareholders and whether legal remedies may be available.

Why it matters — An investor rights law firm has opened a probe into Embecta's leadership, so shareholders may want to follow whether the investigation leads to legal action or findings about management conduct.

EMBC Stock News: Embecta Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 57% Stock Drop

PRNewsWire · 18 Aug 2026negative

A securities fraud class action lawsuit has been filed against Embecta Corp. and certain senior executives by Bleichmar Fonti & Auld LLP, following a stock drop of over 57%. The suit alleges Embecta misled investors about the strength of its insulin pen needle product category, in potential violation of federal securities laws.

Why it matters — Embecta investors face a pending securities fraud class action tied to the company's sharp stock decline and alleged misrepresentations about a core product category.

EMBC Deadline: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit

PRNewsWire · 17 Aug 2026negative

Rosen Law Firm reminded Embecta Corp. investors of the August 17, 2026 lead plaintiff deadline in a securities fraud lawsuit. The reminder covers purchasers of Embecta common stock during the class period from November 25, 2025 to May 4, 2026, who may be entitled to compensation under a contingency fee arrangement.

Why it matters — EMBC watchers would care because it alerts them to an active securities fraud lawsuit and a deadline to participate as lead plaintiff in the case.

EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with SBS Law

PRNewsWire · 17 Aug 2026negative

SBS Law announced a class action lawsuit against Embecta Corp. for alleged violations of securities laws, including Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. Shareholders who purchased EMBC shares during the specified class period are invited to contact the firm regarding lead plaintiff appointments.

Why it matters — The securities fraud lawsuit introduces potential legal and financial exposure for Embecta Corp., which EMBC shareholders should be aware of.

Embecta Corp. Sued for Securities Law Violations - FINAL DEADLINE TODAY - EMBC

PRNewsWire · 17 Aug 2026negative

The DJS Law Group has reminded investors of a class action lawsuit against Embecta Corp. alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. Shareholders who purchased EMBC shares during the stated class period are encouraged to contact the firm regarding possible lead plaintiff appointments, with a final deadline noted.

Why it matters — Embecta investors who bought shares during the class period may be affected by the securities lawsuit and the related lead plaintiff deadline.

FAQ

Frequently asked questions about EMBC stock

What is the EMBC stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Embecta Corp. have a median 12-month price target of $4, with estimates ranging from $3 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EMBC stock a buy right now?

Of the 4 analysts covering Embecta Corp., 0 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Embecta Corp. 84 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EMBC?

As at 21 Aug 2026, Embecta Corp. ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (100 of 100).

Will EMBC stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies -23.5% from the last close, and Ticker Nerd's factor model ranks Embecta Corp. 84 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EMBC stock forecast for 2030?

No analyst covering Embecta Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EMBC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $5 over the next 12 months.

How has EMBC stock performed over the past year?

Embecta Corp. returned -60.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Embecta Corp. do?

Embecta Corporation is a dynamic player in the healthcare industry, primarily focused on producing advanced medical devices. Its chief function is to innovate and manufacture devices related to diabetes care, addressing both individual and clinical needs.

What is the latest news on EMBC?

The most recent item we track (Newsfile Corp, 18 Aug 2026): "EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty". Bernstein Liebhard LLP announced it is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. (NASDAQ: EMBC). The law firm aims to determine whether the company's leadership fulfilled its obligations to shareholders and whether legal remedies may be available.

Company

About Embecta Corp.

Embecta Corporation is a dynamic player in the healthcare industry, primarily focused on producing advanced medical devices. Its chief function is to innovate and manufacture devices related to diabetes care, addressing both individual and clinical needs. The corporation plays a crucial role in providing solutions that facilitate the management of diabetes, which is a growing global health concern. Embecta's products are characterized by their reliability and ease of use, significantly impacting the quality of life for patients and assisting healthcare providers in delivering efficient diabetes management. With a strong emphasis on research and development, Embecta Corporation aims to address the ever-evolving medical necessities associated with diabetes. The company operates globally, ensuring broad access to its innovative medical solutions, thereby positioning itself as a vital contributor to the advancement of healthcare technologies and patient care. Through its continued dedication to excellence and innovation, Embecta Corporation holds significant market relevance, serving both individual customers and larger healthcare systems worldwide.

CEO Mr. Devdatt Kurdikar Ph.D. · 2,100 employees · United States · https://www.embecta.com